Treatment of chronic hepatitis C in liver transplant candidates and recipients: Where do we stand?

Table 2 Doses of antivirals in liver transplant candidates and recipients

Peg-IFN-α 2a	180 μg/wk, subcutaneous	Renal adjustment
Peg-IFN-α 2b	Weight-based 1.5 μg/kg per week, subcutaneous	No CNI adjustment
Ribavirin	Weight-based, 1000 mg in patients < 75 kg, 1200 mg in patients ≥ 75 kg, orally twice a day
Boceprevir	800 mg orally three times a day	No renal adjustment
Telaprevir	1125 mg orally twice a day	CNI adjustment
Sofosbuvir	400 mg daily, orally
Daclatasvir	60 mg daily, orally	No renal adjustment1
Simeprevir	150 mg daily, orally	No CNI adjustment2

¹Sofosbuvir only in patients with glomerular filtration rate > 30 mL/min;

²Simeprevir should not be given with cyclosporine. CNI: Calcineurin inhibitor; Peg-IFN: Pegylated interferon.